# IDeate-Lung02 (NCT06203210)

> A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06203210
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Small Cell Lung Cancer
- Interventions: Ifinatamab deruxtecan; Topotecan; Amrubicin; Lurbinectedin
- Enrollment: 540
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 18

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ideate-lung02-nct06203210

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06203210", "email": "<work email>"}; the inbox owner confirms by the emailed link.